The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease
Language English Country France Media print-electronic
Document type Randomized Controlled Trial, Journal Article
PubMed
36630846
DOI
10.1016/j.biopha.2023.114223
PII: S0753-3322(23)00011-2
Knihovny.cz E-resources
- Keywords
- AChE-Is, Alzheimer’s disease, CSF, Donepezil, Plasma, Ratio,
- MeSH
- Acetylcholinesterase MeSH
- Alzheimer Disease * blood cerebrospinal fluid drug therapy MeSH
- Cholinesterase Inhibitors * blood cerebrospinal fluid therapeutic use MeSH
- Donepezil * blood cerebrospinal fluid therapeutic use MeSH
- Indans therapeutic use pharmacology MeSH
- Humans MeSH
- Piperidines pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Acetylcholinesterase MeSH
- Cholinesterase Inhibitors * MeSH
- Donepezil * MeSH
- Indans MeSH
- Piperidines MeSH
BACKGROUND: The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. METHODS: Forty AD patients receiving 10 mg/day of donepezil were randomly divided into four groups based on the time of plasma and cerebrospinal fluid (CSF) sampling: 6 h (n = 5), 12 h (n = 12), 18 h (n = 6) and 24 h (n = 17) after donepezil administration. High-performance liquid chromatography measured the donepezil concentration in plasma samples and CSF samples collected at 4-time points. RESULTS: Plasma and CSF levels among the groups were not significantly different. Conversely, the CSF/plasma donepezil concentration ratio considerably increased in the 24 h group compared to the 6 h (p < 0.005) and 12 h (p < 0.05) groups. CONCLUSION: The measurement of the CSF/plasma donepezil concentration ratio could be used to better evaluate the optimal dose of donepezil.
References provided by Crossref.org
